Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis

Jadwiga Bienkowska, Allaire Norm, Alice Thai, Jaya Goyal, Tatiana Plavina, Ajay Nirula, Megan Weaver, Charlotte Newman, Michelle Petri, Evan Beckman, Jeffrey L. Browning

Research output: Contribution to journalArticlepeer-review

Abstract

A subset of patients with autoimmune diseases including rheumatoid arthritis (RA) and lupus appear to be exposed continually to interferon (IFN) as evidenced by elevated expression of IFN induced genes in blood cells. In lupus, detection of endogenous chromatin complexes by the innate sensing machinery is the suspected driver for the IFN, but the actual mechanisms remain unknown in all of these diseases. We investigated in two randomized clinical trials the effects on RA patients of baminercept, a lymphotoxin-beta receptor-immunoglobulin fusion protein that blocks the lymphotoxin-ab/LIGHT axis. Administration of baminercept led to a reduced RNA IFN signature in the blood of patients with elevated baseline signatures. Both RA and SLE patients with a high IFN signature were lymphopenic and lymphocyte counts increased following baminercept treatment of RA patients. These data demonstrate a coupling between the lymphotoxin-LIGHT system and IFN production in rheumatoid arthritis. IFN induced retention of lymphocytes within lymphoid tissues is a likely component of the lymphopenia observed in many autoimmune diseases.

Original languageEnglish (US)
Article numbere112545
JournalPloS one
Volume9
Issue number11
DOIs
StatePublished - Nov 18 2014

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint

Dive into the research topics of 'Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this